146 related articles for article (PubMed ID: 18786292)
1. Does paroxetine cause cardiac malformations?
O'Brien L; Einarson TR; Sarkar M; Einarson A; Koren G
J Obstet Gynaecol Can; 2008 Aug; 30(8):696-701. PubMed ID: 18786292
[TBL] [Abstract][Full Text] [Related]
2. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage.
Bérard A; Ramos E; Rey E; Blais L; St-André M; Oraichi D
Birth Defects Res B Dev Reprod Toxicol; 2007 Feb; 80(1):18-27. PubMed ID: 17187388
[TBL] [Abstract][Full Text] [Related]
3. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.
Bérard A; Iessa N; Chaabane S; Muanda FT; Boukhris T; Zhao JP
Br J Clin Pharmacol; 2016 Apr; 81(4):589-604. PubMed ID: 26613360
[TBL] [Abstract][Full Text] [Related]
4. SSRI antidepressants and birth defects.
Prescrire Int; 2006 Dec; 15(86):222-3. PubMed ID: 17167929
[TBL] [Abstract][Full Text] [Related]
5. Counseling pregnant women treated with paroxetine. Concern about cardiac malformations.
Einarson A; Koren G
Can Fam Physician; 2006 May; 52(5):593-4. PubMed ID: 16739830
[TBL] [Abstract][Full Text] [Related]
6. Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence?
Bérard A
Birth Defects Res A Clin Mol Teratol; 2010 Mar; 88(3):171-4. PubMed ID: 19950383
[No Abstract] [Full Text] [Related]
7. Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence.
Einarson A
Can Fam Physician; 2010 Aug; 56(8):767-8. PubMed ID: 20705881
[TBL] [Abstract][Full Text] [Related]
8. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies.
Wurst KE; Poole C; Ephross SA; Olshan AF
Birth Defects Res A Clin Mol Teratol; 2010 Mar; 88(3):159-70. PubMed ID: 19739149
[TBL] [Abstract][Full Text] [Related]
9. Paroxetine exposure during pregnancy and cardiac malformations.
Scialli AR
Birth Defects Res A Clin Mol Teratol; 2010 Mar; 88(3):175-7. PubMed ID: 20175190
[No Abstract] [Full Text] [Related]
10. First trimester exposure to paroxetine and prevalence of cardiac defects: Meta-analysis of the literature: Unfortunately incomplete.
Einarson A; Koren G
Birth Defects Res A Clin Mol Teratol; 2010 Jul; 88(7):588; author reply 589. PubMed ID: 20602457
[No Abstract] [Full Text] [Related]
11. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations.
Myles N; Newall H; Ward H; Large M
Aust N Z J Psychiatry; 2013 Nov; 47(11):1002-12. PubMed ID: 23761574
[TBL] [Abstract][Full Text] [Related]
12. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study.
Bakker MK; Kerstjens-Frederikse WS; Buys CH; de Walle HE; de Jong-van den Berg LT
Birth Defects Res A Clin Mol Teratol; 2010 Feb; 88(2):94-100. PubMed ID: 19937603
[TBL] [Abstract][Full Text] [Related]
13. Paroxetine in the first trimester and the prevalence of congenital malformations.
Cole JA; Ephross SA; Cosmatos IS; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1075-85. PubMed ID: 17729379
[TBL] [Abstract][Full Text] [Related]
14. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births.
Gao SY; Wu QJ; Sun C; Zhang TN; Shen ZQ; Liu CX; Gong TT; Xu X; Ji C; Huang DH; Chang Q; Zhao YH
BMC Med; 2018 Nov; 16(1):205. PubMed ID: 30415641
[TBL] [Abstract][Full Text] [Related]
15. Treacher Collins syndrome with multiple congenital heart defects after paroxetine exposure: case report.
Dinlen N; Zenciroğlu A; Dilli D; Aydin B; Beken S; Okumuş N
Genet Couns; 2014; 25(1):7-11. PubMed ID: 24783649
[TBL] [Abstract][Full Text] [Related]
16. Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Malm H; Artama M; Gissler M; Ritvanen A
Obstet Gynecol; 2011 Jul; 118(1):111-120. PubMed ID: 21646927
[TBL] [Abstract][Full Text] [Related]
17. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.
Bakker MK; Kölling P; van den Berg PB; de Walle HE; de Jong van den Berg LT
Br J Clin Pharmacol; 2008 Apr; 65(4):600-6. PubMed ID: 17953715
[TBL] [Abstract][Full Text] [Related]
18. The fetal safety of fluoxetine: a systematic review and meta-analysis.
Riggin L; Frankel Z; Moretti M; Pupco A; Koren G
J Obstet Gynaecol Can; 2013 Apr; 35(4):362-369. PubMed ID: 23660045
[TBL] [Abstract][Full Text] [Related]
19. Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRD.
Margulis AV; Abou-Ali A; Strazzeri MM; Ding Y; Kuyateh F; Frimpong EY; Levenson MS; Hammad TA
Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):942-51. PubMed ID: 23733623
[TBL] [Abstract][Full Text] [Related]
20. Selective serotonin reuptake inhibitor exposure during early pregnancy and the risk of fetal major malformations: focus on paroxetine.
Gentile S; Bellantuono C
J Clin Psychiatry; 2009 Mar; 70(3):414-22. PubMed ID: 19254517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
